UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-14 | Future report Set alerts | |
| Q2 2022 | 2022-08-11 | -0.09 | -0.09 |
| Q1 2022 | 2022-05-11 | -0.10 | -0.10 |
| Q4 2021 | 2022-03-31 | -0.08 | -0.08 |
| Q3 2021 | 2021-11-15 | -0.08 | -0.08 |
| Q2 2021 | 2021-08-12 | -0.09 | -0.09 |
| Q1 2021 | 2021-05-06 | -0.06 | -0.06 |
| Q4 2020 | 2021-03-09 | -0.08 | -0.08 |
| Q3 2020 | 2020-11-02 | -0.04 | -0.04 |
| Q2 2020 | 2020-08-10 | -0.06 | -0.06 |
| 2016-06-02 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-17 | Reiterated Rating | Wedbush | Outperform | $20.00 to $16.00 |
| 2016-05-17 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 to $11.00 |
| 2016-05-17 | Boost Price Target | FBR & Co. | Outperform | $13.00 to $16.00 |
| 2016-05-17 | Boost Price Target | FBR & Co | Outperform | $13.00 to $16.00 |
| 2016-05-16 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-16 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-14 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-05-05 | Reiterated Rating | Wedbush | Outperform | $20.00 |
| 2016-05-04 | Reiterated Rating | FBR & Co. | Buy | $16.00 |
| 2016-05-03 | Reiterated Rating | Needham & Company LLC | Buy | |
| 2016-05-03 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-03 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-07 | Reiterated Rating | Wedbush | Positive | |
| 2016-03-29 | Initiated Coverage | FBR & Co. | Outperform | $16.00 |
| 2016-03-22 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 |
| 2016-03-15 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-03-10 | Reiterated Rating | Brean Capital | Buy | $14.00 |
| 2016-03-09 | Reiterated Rating | Wedbush | Outperform | $20.00 |
| 2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $21.00 to $18.00 |
| 2016-03-02 | Initiated Coverage | WallachBeth Capital | Buy | $18.00 |
| 2016-02-24 | Lower Price Target | Barclays | Overweight | $18.00 to $15.00 |
| 2016-02-24 | Lower Price Target | Barclays PLC | Overweight | $18.00 to $15.00 |
| 2016-02-23 | Reiterated Rating | Jefferies Group | Buy | $15.00 |
| 2016-02-22 | Reiterated Rating | Cowen and Company | Outperform | $14.00 |
| 2016-02-22 | Reiterated Rating | Wedbush | Outperform | $20.00 |
| 2015-11-17 | Reiterated Rating | Wedbush | Outperform | $20.00 |
| 2015-11-11 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 |
| 2015-11-01 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 |
| 2015-10-29 | Initiated Coverage | Brean Capital | Buy | |
| 2015-09-02 | Reiterated Rating | JMP Securities | Buy | |
| 2015-09-02 | Reiterated Rating | Roth Capital | Buy | |
| 2015-09-02 | Reiterated Rating | Wedbush | Buy | |
| 2015-09-02 | Boost Price Target | Jefferies Group | Buy | $9.00 to $13.00 |
| 2015-09-01 | Reiterated Rating | Cowen and Company | Buy | $13.00 to $14.00 |
| 2015-09-01 | Upgrade | Barclays | Equal Weight to Overweight | $11.00 to $18.00 |
| 2015-09-01 | Reiterated Rating | Needham & Company LLC | Buy to Positive | $14.00 |
| 2015-09-01 | Boost Price Target | Wedbush | Outperform | $15.00 to $20.00 |
| 2015-08-11 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 |
| 2015-08-11 | Reiterated Rating | Brean Capital | Buy | $14.00 |
| 2015-08-03 | Initiated Coverage | Brean Capital | Buy | $14.00 |
| 2015-07-09 | Reiterated Rating | Wedbush | Buy | $15.00 |
| 2015-06-16 | Initiated Coverage | Roth Capital | Buy | $14.50 |
| 2015-05-21 | Initiated Coverage | Barclays | Equal Weight | $11.00 |
| 2015-05-08 | Lower Price Target | Jefferies Group | Buy | $11.00 to $9.00 |
| 2015-05-07 | Set Price Target | Needham & Company LLC | Buy | $14.00 |
| 2015-03-31 | Initiated Coverage | Wedbush | Outperform | $15.00 |
| 2015-03-24 | Reiterated Rating | Cowen and Company | Outperform | $13.00 |
| 2014-12-19 | Initiated Coverage | Cowen and Company | Outperform | $13.00 |
| 2014-11-18 | Boost Price Target | JMP Securities | Outperform | $18.00 to $21.00 |
| 2014-11-18 | Reiterated Rating | Needham & Company LLC | Positive | |
| 2014-02-27 | Initiated Coverage | Needham & Company LLC | Buy | $14.00 |
| 2014-02-26 | Initiated Coverage | JMP Securities | Outperform | $18.00 |
| 2014-02-26 | Initiated Coverage | Barclays | Overweight | $14.00 |
| 2014-02-26 | Initiated Coverage | Jefferies Group | Buy | $11.00 |
| 2016-06-02 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-05-17 | Reiterated Rating | Wedbush | Outperform | $20.00 to $16.00 |
| 2016-05-17 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 to $11.00 |
| 2016-05-17 | Boost Price Target | FBR & Co. | Outperform | $13.00 to $16.00 |
| 2016-05-17 | Boost Price Target | FBR & Co | Outperform | $13.00 to $16.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In TRVN 49 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 8.05M |
| BlackRock Inc. | 2.81M |
| BlackRock Fund Advisors | 2.16M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.63M |
| RENAISSANCE TECHNOLOGIES LLC | 1.10M |
| BlackRock Institutional Trust Company, N.A. | 1.01M |
| STATE STREET CORP | 0.62M |
| FMR LLC | 0.55M |
| GROUP ONE TRADING, L.P. | 0.33M |
| Virtu Financial LLC | 0.29M |
| NORTHERN TRUST CORP | 0.29M |
| CITADEL ADVISORS LLC | 0.26M |
| CAPTRUST FINANCIAL ADVISORS | 0.20M |
| MORGAN STANLEY | 0.19M |
| BlackRock Investment Management, LLC | 0.17M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| New Enterprise Associates 12, Limited Partnership | 18.25% (4811691) | ARDX / ECHO / ECOM / HPTX / OPWR / TNTR / TRVN / ZSAN / |
| Alta Partners VIII, L.P. | 16.65% (4390262) | AGTC / ESPR / IMDZ / NEOT / TRVN / ZSPH / |
| Forest Laboratories Holdings Ltd | 12.87% (3393466) | FRX / TRVN / |
| HealthCare Ventures VIII, L.P. | 9.28% (2446251) | TRVN / |
| GOWEN MAXINE President & CEO | 0.74% (195512) | AKBA / IDRA / TRVN / |
| Lark Michael W. Sr. VP, Research & CSO | 0.37% (98460) | TRVN / |
| MOULDER LEON O JR | 0.19% (50000) | CBST / TRVN / TSRO / |
| Polaris Venture Management Co. V, L.L.C. | 0.14% (36369) | BIND / CERU / FATE / GNCA / TRVN / |
| Deegan Rosamond Sr VP, Bus Dev & Operations | 0.12% (31105) | TRVN / |
| Cuca Roberto Sr. VP and CFO | 0.09% (25000) | TRVN / |
| Limongelli John M Sr. VP,General Counsel & Secy | 0.05% (12000) | TRVN / |
| DOUGHERTY MICHAEL R | 0.03% (7000) | BOTA / CEMP / CPXX / FMI / MRNS / TRVN / VPHM / |
| Nunn Jason Raleigh | 0.02% (4271) | DERM / HPTX / TRVN / TSPT / |
| Soergel David Sr. VP, Clinical Development | 0.01% (1750) | TRVN / |
UM